OptimizeRx (OPRX) Payables (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Payables data on file, last reported at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 9.32% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (down 9.32% YoY), and the FY2025 full-year result was $1.6 million, down 24.12% from the prior year.
• Payables grew to $3.1 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $3.4 million in Q1 2025 to a low of $600729.0 in Q1 2022.
• A 5-year average of $1.8 million and a median of $1.7 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables slumped 36.9% in 2023 and surged 298.46% in 2024, its largest moves.
• Tracing OPRX's Payables over 5 years: stood at $1.5 million in 2022, then soared by 43.68% to $2.2 million in 2023, then declined by 3.19% to $2.2 million in 2024, then declined by 24.12% to $1.6 million in 2025, then jumped by 87.41% to $3.1 million in 2026.
• Business Quant data shows OPRX's Payables at $3.1 million in Q1 2026, $1.6 million in Q4 2025, and $2.0 million in Q3 2025.